X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The two Companies envision that the MSA will lead to clinical and commercial supply agreements for the drug product 186RNL (rhenium liposome) at the appropriate stage of development.
Lead Product(s): Rhenium-186
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Plus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 23, 2021
Details:
The agreement will employ Biocept’s cerebrospinal fluid assay CNSide1 in Plus Therapeutics’ ReSPECT-LM Phase 1/2a clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM), which is cancer in the membranes.
Lead Product(s): Rhenium-186
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Plus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2022
Details:
In preclinical and clinical trials of 186RNL for treating GBM, ReSPECT-GBM, we delivered up to 20x the absorbed dose of radiation versus standard external beam radiation therapy (EBRT), successfully reducing tumors without significant toxicity.
Lead Product(s): Rhenium-186
Therapeutic Area: Oncology Product Name: Rhenium NanoLiposome
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Rhenium NanoLiposome (RNL™) is designed to safely, effectively and conveniently deliver a very high dose of radiation potentially up to 15 times greater than traditional external beam radiation therapy.
Lead Product(s): Rhenium-186
Therapeutic Area: Oncology Product Name: 186RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
University of Texas MD Anderson Cancer Center is now an active clinical trial site in Plus Therapeutics' ongoing ReSPECT™ Phase 1 clinical trial, currently supported by the National Cancer Institute (NCI).
Lead Product(s): Rhenium-186
Therapeutic Area: Oncology Product Name: BMEDA-Chelated Rhenium NanoLiposome
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
Investigational drug RNL™ delivers up to fifteen times the absorbed dose of radiation compared to standard external beam radiation therapy.
Lead Product(s): Rhenium-186
Therapeutic Area: Oncology Product Name: RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
Plus Therapeutics has treated the first patient in the sixth and final cohort of its National Cancer Institute (NCI)-supported, multi-center ReSPECT™ Phase 1 dose-finding clinical trial evaluating Rhenium NanoLiposomes (RNL™) for the treatment of recurrent glioblastoma (GBM).
Lead Product(s): Rhenium-186
Therapeutic Area: Oncology Product Name: RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Plus Therapeutics' abstract regarding lead investigational drug, Rhenium NanoLiposomes, was accepted to the 2020 Society for Neuro-Oncology (SNO) Annual Meeting being held virtually on November 19-21, 2020.
Lead Product(s): Rhenium-186
Therapeutic Area: Oncology Product Name: RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
RNL is designed to safely, effectively, and conveniently deliver a very high dose of radiation, of up to 25 times greater concentration than currently used external beam radiation therapy, directly into the brain tumor for maximum effect.
Lead Product(s): Rhenium-186
Therapeutic Area: Oncology Product Name: RNL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2020
Details:
Plus Therapeutics closed its previously announced definitive agreement to license multiple rare cancer product candidates that includes, Rhenium-186-chelated NanoLiposome from NanoTx Therapeutics.
Lead Product(s): Rhenium-186
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Plus Therapeutics
Deal Size: $137.2 million Upfront Cash: $0.4 million
Deal Type: Licensing Agreement May 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Piramal's expertise across varied technologies makes them a partner of choice for innovators & generic companies worldwide.
